What are the latest funding news in the Longevity Biotech Market? (October 2026)
Whether you're building or investing in the longevity biotech market, our report covers everything you need to know: the players, the money, and what's coming next.
The latest longevity biotech funding deals show investors concentrating capital around companies that can connect aging biology to clear therapeutic mechanisms and clinical milestones.
Across the 12 qualifying financings, disclosed rounds ranged from $1 million to $435 million, with cellular rejuvenation, immune aging, regenerative biology and aging-focused drug discovery attracting most of the capital.
The market remains relatively small in company count, but several programs have already moved from exploratory longevity science into IND-enabling work, human trials or late regulatory development.
And if you want to better understand this new industry, you can download our pitch covering the Longevity Biotech Market.
Insights
- NewLimit represented about 60% of the roughly $727 million raised across these 12 longevity biotech deals, showing how concentrated investor conviction has become around epigenetic reprogramming.
- Seven of the 12 companies were still preclinical, IND-enabling or at an early platform-validation stage, so longevity biotech funding remains heavily weighted toward scientific risk rather than mature commercial businesses.
- Cellular rejuvenation has become a major capital magnet: NewLimit and Life Biosciences alone raised $515 million for epigenetic reprogramming and cellular restoration programs.
- The smallest recent round was ARTAN Bio's $1 million seed, while the largest was NewLimit's $435 million Series C, a 435-fold gap that illustrates the market's unusually wide funding dispersion.
- Investors are increasingly backing specific aging mechanisms such as somatic mutation, blood stem-cell decline, vascular aging and immune deterioration instead of broad anti-aging claims.
- Three companies in the list, Life Biosciences, Juvena Therapeutics and Immunis, had already reached human clinical development, giving the longevity biotech market more clinical validation than a few years ago.
- Veterinary longevity is emerging as its own investable category, with Loyal raising $100 million for canine lifespan-extension drugs and Rejuvenate Bio advancing aging-focused gene therapies in companion animals.
- Diagnostic and validation infrastructure remains a smaller funding category than therapeutics, although Entourage AI's $5 million pre-seed shows growing demand for measurable biological-aging endpoints.
- Recent rounds increasingly fund concrete development milestones such as IND preparation, Phase 1 trials, Phase 2 studies and regulatory submissions, which is making longevity biotech look more like conventional drug development.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us
Funding is rarely spread evenly. See who's soaking up the capital in our longevity biotech market report.
Summary table of the latest funding deals in the Longevity Biotech Market as of October 2026
We define the longevity biotech market as biotechnology aimed at slowing, preventing or reversing biological processes that drive aging.
We include therapeutic developers targeting aging mechanisms and dedicated platforms used to discover or validate those interventions.
We exclude wellness clinics, general supplements, cosmetic anti-aging products and disease treatments without an explicit aging-biology focus.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| ARTAN Bio | 1 July 2026 | $1M | Seed | Longevity Therapeutics & Mutation Repair |
| Gero | 17 June 2026 | $17M | Series B | Aging Drug Discovery & Small-Molecule Therapeutics |
| Reservoir Neuroscience | 17 June 2026 | $3M | Seed Extension | Brain Aging & Vascular Therapeutics |
| Rejuvenate Bio | 8 June 2026 | $6M | Venture Financing | Gene Therapy & Cellular Rejuvenation |
| NewLimit | 2 June 2026 | $435M | Series C | Epigenetic Reprogramming & Cellular Rejuvenation |
| Life Biosciences | 8 April 2026 | $80M | Series D | Epigenetic Reprogramming & Gene Therapy |
| HexemBio | 6 April 2026 | $10.4M | Seed | Stem-Cell Rejuvenation & Immune Aging |
| Entourage AI | 18 March 2026 | $5M | Pre-seed | Aging Biomarkers & Intervention Validation |
| Loyal | 11 February 2026 | $100M | Series C | Geroscience Therapeutics & Canine Longevity |
| Juvena Therapeutics | 12 January 2026 | $33.5M | Series B | Regenerative Biologics & Tissue Aging |
| Cirrus Therapeutics | 2 October 2025 | $11M | Seed | Ocular Aging & Gene Therapy |
| Immunis | 11 January 2025 | $25M | Series A-1 | Immune Aging & Regenerative Biologics |
All the latest funding deals in the Longevity Biotech Market as of October 2026
ARTAN Bio raised $1 million in July 2026 to advance its mutation-focused longevity platform.
When was it?
ARTAN Bio announced the financing on 1 July 2026.
Who are they?
ARTAN Bio develops engineered suppressor-tRNA therapies designed to restore protein production after premature stop mutations.
Geographical focus?
ARTAN Bio is based in St. Petersburg, Florida, while its therapeutic platform is intended for broader pharmaceutical markets.
Why do we include them in the Longevity Biotech Market?
ARTAN Bio directly targets somatic mutations as a driver of biological aging, placing the company in longevity therapeutics and mutation repair.
What is the company stage?
ARTAN Bio is at the preclinical seed stage and is preparing toxicology, manufacturing and IND-enabling work.
How much did they raise?
ARTAN Bio raised $1 million in this financing.
What round is it?
ARTAN Bio raised a seed round.
Why did they raise?
ARTAN Bio raised the capital to move its codon-suppression platform toward IND-enabling studies and eventual first-in-human development.
Failures teach as much as successes. We break down the biggest falls in our longevity biotech market report.
Gero raised $17 million in June 2026 to advance AI-discovered therapies targeting aging biology.
When was it?
Gero's financing was dated 17 June 2026, with broader coverage published shortly afterward.
Who are they?
Gero combines longitudinal health data, AI and physics-based models to identify causal aging mechanisms and develop drugs against them.
Geographical focus?
Gero operates from Singapore and San Francisco and works with pharmaceutical partners internationally.
Why do we include them in the Longevity Biotech Market?
Gero's core platform searches for interventions that modify aging mechanisms, placing the company in aging drug discovery and longevity therapeutics.
What is the company stage?
Gero is at the preclinical platform-validation stage with internally discovered programs and pharmaceutical partnerships.
How much did they raise?
Gero raised $17 million in new financing.
What round is it?
The financing has been reported as a Series B, although some coverage describes it more broadly as a venture financing.
Why did they raise?
Gero raised the capital to advance preclinical therapeutic programs and expand pharmaceutical collaborations.
Reservoir Neuroscience raised $3 million in June 2026 to pursue therapies for vascular aging in the brain.
When was it?
Reservoir Neuroscience's financing was recorded in June 2026, with the offering filing becoming effective on 17 June.
Who are they?
Reservoir Neuroscience develops small molecules designed to repair aging-related dysfunction in brain blood vessels and the blood-brain barrier.
Geographical focus?
Reservoir Neuroscience is based in the San Francisco Bay Area and is developing therapeutics for global pharmaceutical markets.
Why do we include them in the Longevity Biotech Market?
Reservoir Neuroscience treats vascular aging as an upstream biological driver of neurodegeneration, placing it in brain-aging therapeutics and aging drug discovery.
What is the company stage?
Reservoir Neuroscience is preclinical and has identified therapeutic candidates through its vascular-aging organ-chip platform.
How much did they raise?
Reservoir Neuroscience raised approximately $3 million in the financing.
What round is it?
The financing was a seed extension or unclassified venture equity round.
Why did they raise?
Reservoir Neuroscience raised the capital to continue preclinical development of therapies designed to repair aging brain vasculature and the blood-brain barrier.
Rejuvenate Bio raised $6 million in June 2026 to expand aging-focused gene therapy programs.
When was it?
Rejuvenate Bio announced the financing on 8 June 2026.
Who are they?
Rejuvenate Bio develops gene therapies that modify biological pathways involved in aging and chronic age-associated disease.
Geographical focus?
Rejuvenate Bio is U.S.-based, with much of its current development work focused on companion-animal health.
Why do we include them in the Longevity Biotech Market?
Rejuvenate Bio was built specifically around gene therapies for aging biology, placing it in gene therapy and cellular rejuvenation.
What is the company stage?
Rejuvenate Bio is at the preclinical and development stage with several animal-health programs underway.
How much did they raise?
Rejuvenate Bio raised $6 million in the financing.
What round is it?
Rejuvenate Bio described the deal as a financing round rather than assigning it a numbered Series label.
Why did they raise?
Rejuvenate Bio raised the funding to advance its gene-therapy platform, expand its pipeline and support development work linked to its Merck Animal Health collaboration.
Costs are falling fast, and that changes who can buy. Our longevity biotech market report shows where the tipping points are.
NewLimit raised $435 million in June 2026 as its rejuvenation platform moved toward human testing.
When was it?
NewLimit announced its Series C on 2 June 2026.
Who are they?
NewLimit develops epigenetic-reprogramming medicines that aim to make aged cells behave more like young cells without erasing their identity.
Geographical focus?
NewLimit is based in South San Francisco and is developing medicines for global pharmaceutical markets.
Why do we include them in the Longevity Biotech Market?
NewLimit directly targets cellular aging through epigenetic reprogramming, making it a clear cellular rejuvenation and longevity therapeutics pure play.
What is the company stage?
NewLimit is in late preclinical development with its first clinical candidate selected and human testing planned.
How much did they raise?
NewLimit raised $435 million in the round.
What round is it?
NewLimit raised a Series C.
Why did they raise?
NewLimit raised the capital to move its first liver program into clinical development while continuing to build its broader cellular-rejuvenation platform.
Life Biosciences raised $80 million in April 2026 to advance partial epigenetic reprogramming into the clinic.
When was it?
Life Biosciences announced the financing on 8 April 2026.
Who are they?
Life Biosciences develops gene therapies that use partial epigenetic reprogramming to restore youthful cellular function.
Geographical focus?
Life Biosciences is based in Boston and is developing therapies intended for international pharmaceutical markets.
Why do we include them in the Longevity Biotech Market?
Life Biosciences explicitly targets the biology of aging through cellular rejuvenation and epigenetic restoration.
What is the company stage?
Life Biosciences is clinical stage, with ER-100 progressing through a Phase 1 program.
How much did they raise?
Life Biosciences raised $80 million.
What round is it?
Life Biosciences raised a Series D.
Why did they raise?
Life Biosciences raised the capital to fund its Phase 1 ER-100 study, extend its operating runway and develop additional candidates from its reprogramming platform.
HexemBio raised $10.4 million in April 2026 to prepare its stem-cell rejuvenation technology for human trials.
When was it?
HexemBio announced the round on 6 April 2026.
Who are they?
HexemBio rejuvenates aging blood stem cells outside the body before returning the restored cells to patients.
Geographical focus?
HexemBio operates in the United States, with activities associated with New York and Berkeley.
Why do we include them in the Longevity Biotech Market?
HexemBio directly targets declining hematopoietic stem-cell function as a cause of immune aging, placing it in stem-cell rejuvenation and immune aging.
What is the company stage?
HexemBio is in late preclinical and IND-enabling development after completing an FDA pre-IND meeting.
How much did they raise?
HexemBio raised $10.4 million.
What round is it?
HexemBio raised a seed round.
Why did they raise?
HexemBio raised the capital to move its Synthetic Human Yolk Sac technology toward human testing.
Market size is where every investment case starts. Get the full picture in our longevity biotech market report.
Entourage AI raised $5 million in March 2026 to launch its proteomic biological-aging platform.
When was it?
Entourage AI announced the financing on 18 March 2026.
Who are they?
Entourage AI uses mass-spectrometry proteomics and AI to measure biological age and organ-level health from circulating proteins.
Geographical focus?
Entourage AI is based in Glasgow and is targeting customers in the UK, U.S. and international research markets.
Why do we include them in the Longevity Biotech Market?
Entourage AI is a dedicated aging-measurement platform that can quantify biological aging and help validate whether longevity interventions are working.
What is the company stage?
Entourage AI is at commercial launch and very early product-market-fit stage, with its research facility operating and initial products entering the market.
How much did they raise?
Entourage AI raised $5 million.
What round is it?
Entourage AI raised a pre-seed round.
Why did they raise?
Entourage AI raised the capital to build its Glasgow research operation, expand its proteomic datasets and launch its Aging Clock and Organ Health products.
Loyal raised $100 million in February 2026 as its canine longevity drug moved closer to market.
When was it?
Loyal announced the Series C on 11 February 2026.
Who are they?
Loyal develops prescription medicines designed to target biological drivers of canine aging and extend healthy lifespan.
Geographical focus?
Loyal is initially focused on the U.S. companion-animal market.
Why do we include them in the Longevity Biotech Market?
Loyal's drugs are designed to extend lifespan by intervening in aging biology itself, placing the company in geroscience therapeutics and canine longevity.
What is the company stage?
Loyal is in late clinical and regulatory development and is preparing for potential commercialization.
How much did they raise?
Loyal raised $100 million.
What round is it?
Loyal raised a Series C.
Why did they raise?
Loyal raised the capital to complete remaining FDA work for LOY-002, prepare manufacturing and support a future commercial launch.
Juvena Therapeutics raised $33.5 million in January 2026 to expand its regenerative biologics pipeline.
When was it?
Juvena Therapeutics announced its financing on 12 January 2026.
Who are they?
Juvena Therapeutics identifies proteins secreted by human stem cells and engineers them into biologics that restore damaged tissue signaling and function.
Geographical focus?
Juvena Therapeutics is based in the San Francisco Bay Area and is developing medicines for global pharmaceutical markets.
Why do we include them in the Longevity Biotech Market?
Juvena Therapeutics develops regenerative factors for sarcopenia, frailty and age-related loss of tissue-repair capacity, placing it in regenerative biologics and tissue aging.
What is the company stage?
Juvena Therapeutics is clinical stage, with JUV-161 having entered human testing.
How much did they raise?
Juvena Therapeutics raised $33.5 million.
What round is it?
Juvena Therapeutics raised a Series B.
Why did they raise?
Juvena Therapeutics raised the funding to advance clinical programs, expand its regenerative-biologics pipeline and develop its AI-enabled discovery platform.
Want to see how much of this market is real today? Find out in our longevity biotech market report.
Cirrus Therapeutics raised $11 million in October 2025 to advance an aging-focused ocular gene therapy.
When was it?
Cirrus Therapeutics announced the seed financing on 2 October 2025.
Who are they?
Cirrus Therapeutics develops ocular gene and cell therapies that restore immune-regulatory mechanisms lost as the eye ages.
Geographical focus?
Cirrus Therapeutics operates from Cambridge, Massachusetts, and has also expanded into Singapore.
Why do we include them in the Longevity Biotech Market?
Cirrus Therapeutics targets age-driven loss of IRAK-M and immune homeostasis, placing the company in ocular aging and gene therapy.
What is the company stage?
Cirrus Therapeutics is preclinical and progressing through IND-enabling development.
How much did they raise?
Cirrus Therapeutics raised $11 million.
What round is it?
Cirrus Therapeutics raised a seed round.
Why did they raise?
Cirrus Therapeutics raised the capital to complete IND-enabling work for its lead program and develop additional ocular-aging therapies.
Immunis raised $25 million in January 2025 to fund Phase 2 studies of its age-related regenerative biologic.
When was it?
Immunis announced the Series A-1 financing on 11 January 2025.
Who are they?
Immunis develops stem-cell-derived multi-active biologics intended to restore immune, muscle and metabolic function that declines with age.
Geographical focus?
Immunis is based in Irvine, California, with current clinical development focused on older adults in the United States.
Why do we include them in the Longevity Biotech Market?
Immunis directly targets age-related immune decline and its effects on muscle and metabolism, placing it in immune aging and regenerative biologics.
What is the company stage?
Immunis is clinical stage and is advancing Phase 2 development after completing earlier human testing.
How much did they raise?
Immunis raised $25 million.
What round is it?
Immunis raised a Series A-1.
Why did they raise?
Immunis raised the capital to fund randomized Phase 2 studies of IMM01-STEM in older adults with muscle and metabolic decline.
Most startups here don't fail for lack of money. Our longevity biotech market report shows what really kills them.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us